Mylan INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$1.1Mgeneral payments (2019-2025)
$106Kresearch payments (2019-2025)
308clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Yupelri $31K associated (2023-2025)
- Zoloft $31K associated (2023-2025)
- Effexor $30K associated (2023-2025)
- Lyrica $28K associated (2023-2025)
- Clozapine $27K associated (2023-2025)
- Tobi Podhaler $21K associated (2023-2025)
- Giapreza $16K associated (2023-2025)
- Xanax $15K associated (2023-2025)
- Norvasc $10K associated (2023-2025)
- Byfavo $9,586 associated (2023-2025)
- Revatio $7,854 associated (2023-2025)
- Xerava $6,000 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Sripal Bangalore | New York, NY | Interventional Cardiology | $194,901.30 |
| Rakesh Jain | Lake Jackson, TX | Psychiatry | $106,101.24 |
| Christoph Correll | Glen Oaks, NY | Psychiatry | $102,652.44 |
| Marc Berger | New York, NY | Internal Medicine | $92,062.35 |
| Hope Rugo | San Francisco, CA | Hematology (Internal Medicine) | $41,952.74 |
| Jill Ohar | Winston Salem, NC | Pulmonary Disease | $22,621.94 |
| Aaron Milstone | Franklin, TN | Pulmonary Disease | $21,368.13 |
| John Mulhall | New York, NY | Urology | $20,719.10 |
| Antonio Anzueto | San Antonio, TX | Pulmonary Disease | $18,572.51 |
| Rodica Busui | Portland, OR | Endocrinology, Diabetes & Metabolism | $18,351.20 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.